Abstract
I read with interest the article by Donadio et al.1 on skin nerve α-synuclein deposits as a new potential biomarker for dementia with Lewy bodies (DLB). Articles have been published on synuclein deposition in peripheral nerves in Parkinson disease (PD) as well,2,3 which the authors noted in the introduction.1 Within this study, can synucleinopathies be differentiated (e.g., DLB from PD, pure autonomic failure, or multiple system atrophy)? If the presence of phosphorylated α-synuclein on skin biopsy cannot differentiate between these synucleinopathies, then why perform this study? Would not a positive result be expected even before beginning the study?
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
